Brief: Defloria Announces Positive Results From Phase 1 Trial Of AJA001 Being Developed For The Treatment Of Autism Spectrum Disorder (Asd)

Charlotte's Web Holdings

12/12/2024 13:04

Dec 12 (Reuters) - Charlotte's Web Holdings  CWEB.TO :
    * DEFLORIA ANNOUNCES POSITIVE RESULTS FROM PHASE 1 TRIAL OF
AJA001
BEING DEVELOPED FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER
(ASD)
    * DEFLORIA- AJA001 TRIAL DEMONSTRATES SAFETY AND
TOLERABILITY FOR
ASD
    * DEFLORIA: AJA001 WAS WELL-TOLERATED AT DOSES UP TO 680 MG
PER
DAY AS A SINGLE DOSE, UP TO 660 MG PER DAY ADMINISTERED TWICE A
DAY

Source text:  ID:nPn84N7zLa 
Further company coverage:  CWEB.TO 

 ((Reuters.Briefs@thomsonreuters.com;))